Akèy › Leksemi limfositik egi
Etid klinik pou Leksemi limfositik egi ap rekrite nan Etazini
8 etid pou Leksemi limfositik egi ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07566364Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT06580002Halt Aging in Survivors of Blood Cancers
Ap rekrite
Laj 50 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT07292272211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03670966Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Ap rekriteEtid obsèvasyon
Jiska laj 26 · Tout sèks · Mizajou Jun 4, 2026 · NCT05865301A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou May 28, 2026 · NCT03219450Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Ap rekriteFaz 2
Laj 1 a 60 · Tout sèks · Mizajou Mar 12, 2026 · NCT03970096Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.